Akcea Therapeutics (AKCA) Tops Q3 EPS by 7c

Akcea Therapeutics (NASDAQ: AKCA) reported Q3 EPS of ($0.73), $0.07 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $19.24 million versus the consensus estimate of $16.82 million.

Akcea had $320 million of cash, cash equivalents and short-term investments as of September 30, 2018.

For earnings history and earnings-related data on Akcea Therapeutics (AKCA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04
• RCM Technologies (RCMT) Tops Q2 EPS by 17c